5:49 PM
 | 
Apr 29, 2013
 |  BC Extra  |  Company News

Complete response for Gilead's cobicistat, elvitegravir

Gilead Sciences Inc. (NASDAQ:GILD) said it received complete response letters from FDA for a pair of NDAs for elvitegravir and cobicistat. Gilead was seeking approval of elvitegravir to treat HIV-1 infection in treatment-experienced...

Read the full 154 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >